in vivo News and Research

RSS

Inhibition of parvalbumin-expressing prefrontal interneurons triggers fear behaviours

Using an approach combining in vivo recordings and optogenetic manipulations in mice, the researchers succeeded in showing that the inhibition of parvalbumin-expressing prefrontal interneurons triggers a chain reaction resulting in fear behaviour. Conversely, activation of these parvalbumin interneurons significantly reduces fear responses in rodents.

22 Nov 2013

Covagen, TRL expand research collaboration to generate bispecific FynomAb

Covagen and Tanabe Research Laboratories U.S.A, Inc., a fully owned subsidiary of Mitsubishi Tanabe Pharma Corporation, today announced that they expanded their strategic research collaboration. MTPC and TRL have nominated a first bispecific FynomAb for formal preclinical development which triggered an undisclosed milestone payment. MTPC and TRL also exercised an option for a second bispecific FynomAb program based on the parties' research and licensing agreement signed in October 2012.

21 Nov 2013

Using radiation models to improve cancer therapies: an interview with Adrian Treverton, COO of Xstrahl and Jean-Pierre Wery, President of Crown Bioscience

What we are trying to do is take a cancer model like the PDX model (patient-derived tumor xenograft), which is a human-derived cancer growing in an in vivo model and apply radiation to that model.

From Xstrahl 20 Nov 2013

Medix Biochemica to launch antibody production services for IVD assays at MEDICA 2013

Medix Biochemica, producer of monoclonal antibodies for the global IVD industry and diagnostic rapid tests, is presenting its MedixMAB by Design and MedixMAB Manufacturing antibody production services to the European market at MEDICA 2013, Dusseldorf, Germany, 20-23 November, Hall 3, Stand F44.

14 Nov 2013

Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Cancer can be treated by a number of different ways depending on the location, grade and stage of tumour. A patient's age, medical history and lifestyle will also be taken into consideration and a combination of treatments will also be adopted to provide maximum effect.

14 Nov 2013

Promethera Biosciences completes patient enrolment for first clinical trial of HepaStem

Promethera Biosciences, a Belgian biotechnology company developing Promethera HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, announces today the completion of patient enrolment for its first clinical trial.

12 Nov 2013

Generating an alternative to IVIG therapy: an interview with Professor Richard Pleass, LSTM

IVIG is a hugely successful biological with FDA approval for treating idiopathic thrombocytopenic purpura (ITP), Kawasaki disease, Guillain-Barré syndrome, Graves ophthalmopathy and numerous polyneuropathies.

11 Nov 2013

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

GW Pharmaceuticals plc a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme.

11 Nov 2013

BioInvent International receives US patent for drug discovery technology F.I.R.S.T.

BioInvent International AB today announces that it has been granted a US patent for its antibody and concomitant target discovery technology F.I.R.S.T.

11 Nov 2013

Researchers reveal that reduction in mitochondrial DNA may lead to metastasis of breast cancer cells

For years, scientists have observed that tumor cells from certain breast cancer patients with aggressive forms of the disease contained low levels of mitochondrial DNA. But, until recently, no one was able to explain how this characteristic influenced disease progression.

11 Nov 2013

Lowa researchers create bio patch that regenerates missing or damaged bone

Researchers at the University of Iowa have created a bio patch to regenerate missing or damaged bone by putting DNA into a nano-sized particle that delivers bone-producing instructions directly into cells.

8 Nov 2013

Study reveals that lower dose of BPA contributes to large range of health problems in humans

Bisphenol A (BPA) is a known endocrine disruptor that hijacks the normal responses of hormones. Yet, traditional toxicology studies indicate that only very high doses of this chemical affect exposed animals-doses as high as 50 mg/kg/day.

8 Nov 2013

Researchers identify new class of anti-inflammatory drugs may be used to treat IBD

Researchers in UCD Conway Institute and Systems Biology Ireland have identified a way that a new class of anti-inflammatory drugs may be used to treat inflammatory bowel disease (IBD).

7 Nov 2013

Can-Fite BioPharma executes confidentiality agreements for commercialization of CF101 drug

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it executed confidentiality agreements with 10 established pharmaceutical and biotechnology companies with respect to potential negotiations for the commercialization of CF101 for the treatment of autoimmune inflammatory indications.

4 Nov 2013

Reinnervate, Oncotest and SBH partner to offer 3D tumour cell screening services

3D cell culture company Reinnervate Ltd today announced partnerships with two oncology-focussed CRO's to offer 3D tumour cell screening services. The CROs, Oncotest GmbH (Freiburg, Germany) and SBH Sciences (Natick, MA, USA) will both offer a new service for clients wishing to try out cancer 3D cell culture screening for the first time or who wish to evaluate new tumour types in their models.

31 Oct 2013

Immune Design closes Series C financing totalling up to $49M

Immune Design, a biotechnology company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced it has closed a Series C financing totalling up to $49 million.

30 Oct 2013

UCR, CRF initiate PROSPECT II trial to identify plaques that may lead to coronary events

The Cardiovascular Research Foundation (CRF) of New York, NY and the Uppsala Clinical Research Center (UCR) of Uppsala, Sweden announced today the initiation of the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) II trial and the PROSPECT ABSORB sub study.

29 Oct 2013

UMMS professor receives EUREKA grant to develop light activated nanoparticles for imaging brain tissue

University of Massachusetts Medical School Assistant Professor of Biochemistry and Molecular Pharmacology Gang Han, PhD, has received a $1.3 million EUREKA (Exceptional Unconventional Research Enabling Knowledge Acceleration) grant from the National Institute of Mental Health to develop light activated nanoparticles that can be used to image live brain tissue.

25 Oct 2013

Diffregen awarded SBIR Phase 1 grant to advance Angiocidin towards human clinical trials

Diffregen LLC, a Temple University startup company, has been awarded a small business innovation research Phase 1 grant by the National Cancer Institute to advance Angiocidin, a university-created therapeutic to treat acute myeloid leukemia, to the doorstep of human clinical trials.

24 Oct 2013

New technological approach may help improve stem cell-based neurodegenerative diseases

An international research group has successfully tested the use of a new type of porous material for the efficient delivery of key molecules to transplanted cells derived from stem cells. These results can lead to improvements in the way stem cell-based neurodegenerative diseases are treated.

23 Oct 2013

in vivo News and Research

Inhibition of parvalbumin-expressing prefrontal interneurons triggers fear behaviours

Covagen, TRL expand research collaboration to generate bispecific FynomAb

Using radiation models to improve cancer therapies: an interview with Adrian Treverton, COO of Xstrahl and Jean-Pierre Wery, President of Crown Bioscience

Medix Biochemica to launch antibody production services for IVD assays at MEDICA 2013

Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Promethera Biosciences completes patient enrolment for first clinical trial of HepaStem

Generating an alternative to IVIG therapy: an interview with Professor Richard Pleass, LSTM

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

BioInvent International receives US patent for drug discovery technology F.I.R.S.T.

Researchers reveal that reduction in mitochondrial DNA may lead to metastasis of breast cancer cells

Lowa researchers create bio patch that regenerates missing or damaged bone

Study reveals that lower dose of BPA contributes to large range of health problems in humans

Researchers identify new class of anti-inflammatory drugs may be used to treat IBD

Can-Fite BioPharma executes confidentiality agreements for commercialization of CF101 drug

Reinnervate, Oncotest and SBH partner to offer 3D tumour cell screening services

Immune Design closes Series C financing totalling up to $49M

UCR, CRF initiate PROSPECT II trial to identify plaques that may lead to coronary events

UMMS professor receives EUREKA grant to develop light activated nanoparticles for imaging brain tissue

Diffregen awarded SBIR Phase 1 grant to advance Angiocidin towards human clinical trials

New technological approach may help improve stem cell-based neurodegenerative diseases

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News